Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Tannaz Armaghany
- Target Recruit Count
- 6
- Registration Number
- NCT03515941
- Locations
- 🇺🇸
Baylor St. Lukes Medical Center, Houston, Texas, United States
🇺🇸Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
🇺🇸Harris Health System- Smith Clinic, Houston, Texas, United States
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT03505320
- Locations
- 🇫🇷
Site FR33003, Pessac, Nouvelle-Aquitaine, France
🇫🇷Site FR33002, Poitiers, Nouvelle-Aquitaine, France
🇫🇷Site FR33001, Brest, France
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- SuZhou Stainwei Biotech Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03503604
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 566
- Registration Number
- NCT03504397
- Locations
- 🇺🇸
St. Jude Hospital Yorba Linda, Fullerton, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 146
- Registration Number
- NCT03493048
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
First-line Therapy in Metastatic PDAC
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 270
- Registration Number
- NCT03487016
- Locations
- 🇩🇪
Klinikum der Universitaet Muenchen - Campus Grosshadern, Munich, Germany
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT03469557
- Locations
- 🇨🇳
Fifth Medical Center of Pla General Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Post Marketing Surveillance Study for ONIVYDE® in South Korea
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 94
- Registration Number
- NCT03446872
- Locations
- 🇰🇷
Konyang University Hospital, Daejeon, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷ASAN Medical Center, Seoul, Korea, Republic of
SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 130
- Registration Number
- NCT03443492
- Locations
- 🇨🇳
National Institute of Cancer Research, Miaoli, Taiwan
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 674
- Registration Number
- NCT03421288
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇨🇭SAKK Coordinating Center, Bern, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.